LISCURE BIOSCIENCES CO. LTD.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
LISCure Expands Global Partnerships for BBB Shuttle Platform 'ExoPN-101'; Signs Fourth MTA with Leading Pharma Partner 2025-11-13 21:00
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC) 2025-11-10 20:00
LISCure BioSciences Secures World's First Approval for "Joint Health Probiotic" as Recognized Health Functional Ingredient 2025-10-22 14:28
LISCure BioSciences Secures World's First FDA NDI notification for Hair Health Probiotic Mobiome® 2025-09-09 13:41
LISCure Biosciences Secures World's First Regulatory Approval for Hair Health Probiotic as an functional Ingredient 2025-03-20 21:00
LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC) 2024-03-29 21:00
Celltrion and LISCure Biosciences announce strategic collaboration to develop novel microbiome treatment for Parkinson's disease 2023-02-20 22:00
LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA 2022-12-08 22:00
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022 2022-10-28 21:00
LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology 2022-02-03 22:00
LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases 2022-01-06 22:00
LISCure Biosciences received clinical approval for two microbiome programs targeting autoimmune disease and NASH 2021-09-30 21:00
LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic 2021-08-02 11:11
LISCure Biosciences Successfully Raises $21 million in Series B Funding 2021-02-26 22:00
LISCure Biosciences Has Completed Seed Funding of USD 5 Million for Bacteria-mediated Immunotherapy R&D Enhancement 2019-07-25 21:00
1